The Deal Recognizes Arnold & Porter's Transactional Work for Pfizer as 'Healthcare & Pharma Deal of the Year'
Arnold & Porter's representation on behalf of Pfizer Inc. (Pfizer) for its creation of Cerevel Therapeutics, LLC (Cerevel) was awarded "Healthcare & Pharma Deal of the Year" by The Deal Awards Middle Market 2019. The transaction was also shortlisted for "Most Innovative Deal of the Year," and the firm's work representing Halifax Group in its acquisition of ChanceLight was shortlisted for "Healthcare & Pharma Deal of the Year."
The Deal Awards celebrate "the leaders of the deal economy" by recognizing "leading lawyers, bankers, investors and advisors in middle-market transactions." Corporate & Finance partners Lowell Dashefsky and Aaron Gardner accepted the award on March 26, 2019 at The Deal Awards ceremony in Chicago, IL.
Arnold & Porter advised Pfizer on its joint creation of Cerevel, a new biopharmaceutical company focused on developing drug candidates to treat central nervous system disorders (CNS), with Bain Capital, LP (Bain Capital). Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel and will retain a 25% equity position in the company, while Bain Capital's affiliated funds have committed $350 million with the ability to provide additional capital if needed.
The Arnold & Porter transaction team was led by Corporate and Finance partners Lowell Dashefsky and Aaron Gardner and associate Danielle Rosato with support from Tax partner Laurie Abramowitz, senior associate Sarah Soloveichik and associate Zeno Houston.